Park National Corp OH Buys 2,959 Shares of Becton, Dickinson and Company $BDX

Park National Corp OH grew its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 6.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 45,537 shares of the medical instruments supplier’s stock after buying an additional 2,959 shares during the period. Park National Corp OH’s holdings in Becton, Dickinson and Company were worth $8,523,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Saudi Central Bank bought a new stake in shares of Becton, Dickinson and Company during the 1st quarter valued at about $26,000. Bell Investment Advisors Inc increased its holdings in shares of Becton, Dickinson and Company by 474.1% in the 2nd quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 128 shares during the last quarter. Kelly Lawrence W & Associates Inc. CA purchased a new stake in shares of Becton, Dickinson and Company during the 1st quarter valued at $31,000. Bank of Jackson Hole Trust lifted its holdings in shares of Becton, Dickinson and Company by 85.6% during the 2nd quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock worth $35,000 after acquiring an additional 95 shares during the last quarter. Finally, WPG Advisers LLC purchased a new position in Becton, Dickinson and Company in the first quarter worth $36,000. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Down 0.3%

NYSE BDX opened at $200.37 on Tuesday. Becton, Dickinson and Company has a 1 year low of $162.29 and a 1 year high of $251.99. The stock has a market capitalization of $57.19 billion, a PE ratio of 34.37, a PEG ratio of 1.86 and a beta of 0.25. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.11 and a quick ratio of 0.64. The business’s 50-day moving average is $189.07 and its 200 day moving average is $184.85.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. The business had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%. Sell-side analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 31st. Investors of record on Monday, December 8th will be issued a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.1%. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date is Monday, December 8th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 72.04%.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 217 shares of the company’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $176.58, for a total value of $38,317.86. Following the completion of the transaction, the director directly owned 35,816 shares in the company, valued at approximately $6,324,389.28. This represents a 0.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders have sold 407 shares of company stock worth $73,922. 0.36% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Wall Street Zen lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Piper Sandler cut their price objective on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a research note on Friday, November 7th. Jefferies Financial Group lifted their target price on shares of Becton, Dickinson and Company from $215.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, December 10th. Argus boosted their price target on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Finally, Morgan Stanley lifted their price objective on Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a report on Tuesday, December 2nd. Four investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $204.91.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.